Full video transcriptClick to expand
Auto-generated transcript of @thedebway's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:01Tell me, now you're greater
- 0:03You're new, boy
@thedebway's 'food noise' claim about Wegovy vs Mounjaro
Quick answer
Tirzepatide and semaglutide are both GLP-1 receptor agonists, but tirzepatide also targets GIP receptors. Head-to-head trials show tirzepatide produces greater weight loss (20.9% vs 14.9% at maximum doses) and may provide superior appetite suppression through its dual incretin mechanism.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @thedebway's 'food noise' claim about Wegovy vs Mounjaro, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Compounded Semaglutide should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@thedebway's 'food noise' claim about Wegovy vs Mounjaro" from 🌷 Deb 🌷. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide and semaglutide are both GLP-1 receptor agonists, but tirzepatide also targets GIP receptors.
The reason this review is not generic is the source wording and the canonical claim label "glp1 the food noise is back and it s not the same as being on mj." In this clip, the useful excerpt is: "Tell me, now you're greater You're new, boy" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide and semaglutide are both GLP-1 receptor agonists, but tirzepatide also targets GIP receptors.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide and semaglutide are both GLP-1 receptor agonists, but tirzepatide also targets GIP receptors. Head-to-head trials show tirzepatide produces greater weight loss (20.9% vs 14.9% at maximum doses) and may provide superior appetite suppression through its dual incretin mechanism.
- Tirzepatide achieved 20.9% weight loss versus semaglutide's 14.9% in major clinical trials
- Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only targets GLP-1
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Tirzepatide achieved 20.9% weight loss versus semaglutide's 14.9% in major clinical trials
- Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only targets GLP-1
- The SURPASS-2 trial showed tirzepatide led to 11.2kg weight loss versus 5.7kg with semaglutide
- Dose matters significantly when comparing these medications
- Individual responses to GLP-1 medications can vary considerably between patients
- Insurance-driven medication switches don't always account for pharmacological differences
- Maximum dose semaglutide (2.4mg) still trails maximum dose tirzepatide (15mg) in most studies
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
@thedebway says her "food noise" returned after switching from Mounjaro (tirzepatide) to Wegovy (semaglutide), suggesting Mounjaro worked better for controlling food cravings. She's describing the mental chatter about food that many people experience when not on GLP-1 medications.
The video implies tirzepatide might be more effective than semaglutide for appetite suppression. This is actually a pretty common experience that matches what we're seeing in head-to-head studies.
Does the science back this up?
Yes, and the data is quite clear about this. The SURPASS-2 trial (Frías et al., NEJM, 2021) directly compared 15mg tirzepatide to 1mg semaglutide in people with type 2 diabetes. Tirzepatide led to 11.2kg weight loss versus 5.7kg with semaglutide at 40 weeks.
The mechanism explains why. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide only hits GLP-1. GIP affects insulin sensitivity and may have additional appetite effects through different brain pathways.
@thedebway's experience matches what we'd expect based on the dual receptor action.
What's missing from her account?
She doesn't mention doses, which matters enormously here. The SURPASS-2 trial used 1mg semaglutide, but Wegovy goes up to 2.4mg. At maximum doses, the gap narrows considerably, though tirzepatide still appears superior.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 15mg tirzepatide achieved 20.9% weight loss at 72 weeks. The STEP 1 trial with 2.4mg semaglutide hit 14.9% at 68 weeks. Still a meaningful difference, but not as dramatic as lower-dose comparisons suggest.
Why might someone experience this switch?
Insurance coverage often forces these medication switches, and the transition isn't always smooth. Different GLP-1 drugs have varying half-lives and receptor binding patterns. Semaglutide has a 7-day half-life, while tirzepatide lasts about 5 days.
Some people do better on one versus the other, even at equivalent doses. The dual incretin approach of tirzepatide seems to provide more consistent appetite suppression for many patients, though individual responses vary significantly.
What should you actually know?
@thedebway's experience reflects real pharmacological differences between these medications. Tirzepatide does appear more effective for weight loss and appetite control in most people, based on current trial data.
But medication switches should involve dose optimization and timing considerations. If you're switching from tirzepatide to semaglutide, you'll likely need the full 2.4mg dose to get comparable effects. Don't assume the drugs are interchangeable at any dose level.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
🌷 Deb 🌷 · TikTok creator
698.1K views on this video
the food noise is BACK and it’s not the same as being on MJ 😭 #wegovy #wegovyupdate #mounjaro #mounjarotok #mounjaroupdate
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide achieved 20.9% weight loss versus semaglutide's 14.9% in major?
Tirzepatide achieved 20.9% weight loss versus semaglutide's 14.9% in major clinical trials
What does the video say about tirzepatide targets both glp-1?
Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only targets GLP-1
What does the video say about the surpass-2 trial showed tirzepatide led to 11.2kg weight loss?
The SURPASS-2 trial showed tirzepatide led to 11.2kg weight loss versus 5.7kg with semaglutide
Dose matters significantly when comparing these medications?
Dose matters significantly when comparing these medications
What does the video say about individual responses to glp-1 medications can vary considerably between patients?
Individual responses to GLP-1 medications can vary considerably between patients
What does the video say about insurance-driven medication switches don't always account for pharmacological differences?
Insurance-driven medication switches don't always account for pharmacological differences
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by 🌷 Deb 🌷, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.